IMTX
Immatics N.V. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 35 | 0 | 11.76M | $118.95M | +4 | −4 |
| Q1 2026 | 35 | +3 | 20.34M | $199.85M | +5 | −2 |
| Q4 2025 | 31 | 0 | 13.12M | $137.78M | n/a | n/a |
| Q3 2025 | 11 | +1 | 6.87M | $58.55M | +2 | −1 |
| Q2 2025 | 7 | -1 | 7.51M | $36.14M | n/a | −1 |
| Q1 2025 | 7 | -3 | 10.10M | $41.98M | n/a | −3 |
| Q4 2024 | 10 | +1 | 14.90M | $100.53M | +2 | −1 |
| Q3 2024 | 8 | 0 | 16.54M | $184.94M | +1 | −1 |
| Q2 2024 | 8 | n/a | 15.53M | $176.70M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 9.68M | +1.5% | $110.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | T. Rowe Price ✦ | 3.49M | -4.0% | $39.87M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 1.92M | +116.9% | $21.92M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 721.25K | -4.0% | $8.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 393.67K | +19.3% | $1.49M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 194.37K | -11.1% | $1.42M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Geode Capital Management ✦ (passive) | 110.01K | -0.2% | $1.26M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 26.10K | New | $297,801 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $297,801 | 0.0% |
Exited
| Millennium Management | $678,201 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 82 holders, 108.05M shares, $842.81M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 863.06K sh @ 8.69 · $7.50M
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.6% of class · View original SEC filing ↗